NCT06865222 Post COVID-19 Syndrome Treatment With Variable Pulse Transcranial Magnetic Stimulation
| NCT ID | NCT06865222 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Post COVID-19 Condition |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-07-22 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-07-22 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to test if Variable Pulse TMS (Transcranial Magnetic Stimulation) can result in objective improvements in patients with Post COVID Syndrome (PCS).
Eligibility Criteria
Inclusion Criteria: * Patients who have had a recent episode of COVID-19 and who present to the Post COVID-19 Clinic at Mayo Clinic Rochester with at least one of the PCC symptoms of interest - anosmia, tinnitus, fatigue. Symptoms consistent with PCC lasting at least 1 month after the positive test date. Subjects must have ongoing symptoms for \> 4 weeks following the start of an acute covid infection. This is consistent with the CDC definition for post covid conditions. Start date is determined by date of first positive COVID test. There is no limitation of maximum time from acute infection start. * At least one of the PCC symptoms of interest: * Anosmia: Olfactory Threshold Test scores corresponding to Anosmia or Hyposmia * Tinnitus: \>0 score on Tinnitus Handicap Inventory (not present prior to SARS-COVID 2 infection) * Fatigue: Total Modified Fatigue Impact Scale (MFIS) Score of 40 or above Exclusion Criteria: * Implanted electronic devices, including pacemakers, defibrillators, implant medication pumps, or vagus nerve stimulators (VNS) * Active alcohol abuse: \>14 drinks a week or formal diagnosis, illicit drug use or drug abuse * Any seizure history within the past 10 years * Intracranial implant within 30 cm of magnet (e.g., aneurysm clips, endovascular coil, cerebral shunts, brain stimulators, cochlear implants, stents, or electrodes) or any other metal object within or near the head, excluding the mouth, which cannot be safely removed * Enrolled or plans to enroll in an interventional trial during this study * Previous stroke with residual deficits * Subjects unable to comprehend or follow verbal commands * Subjects unable to comprehend and sign the informed consent * Based on PI's or local physician's assessment that subject unable to tolerate the trial procedure due to medical condition * Clinical abnormality or clinically unstable medical condition, as indicated by medical history, physical examination, or clinical laboratory testing, that in the Investigator's judgment might pose a potential safety risk to the subject or limit interpretation of the trial results * Pregnant or trying to become pregnant; negative urine pregnancy test at screening will be required for females of childbearing potential * Any condition which in the judgment of the investigator would prevent the subject from completion of the study
Contact & Investigator
Ryan T. Hurt, M.D.
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT06865222 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Post COVID-19 Condition. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06865222 currently recruiting?
Yes, NCT06865222 is actively recruiting participants. Contact the research team at domresearchhub@mayo.edu for enrollment information.
Where is the NCT06865222 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06865222 clinical trial?
NCT06865222 is sponsored by Mayo Clinic. The principal investigator is Ryan T. Hurt, M.D. at Mayo Clinic. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.